Drug Profile
AAV hFIX - REGENXBIO
Alternative Names: Factor IX gene therapy - REGENXBIO; FIX gene therapy - REGENXBIO; scAAV 2/8-LP1-hFIXcoLatest Information Update: 19 Jan 2024
Price :
$50
*
At a glance
- Originator ReGenX Biosciences
- Developer St. Jude Childrens Research Hospital; University College London
- Class Antihaemorrhagics; Blood coagulation factors; Coagulants; Gene therapies
- Mechanism of Action Gene transference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Haemophilia B
Most Recent Events
- 14 Dec 2011 Phase-I/II clinical trials in Haemophilia B in United Kingdom (IV)
- 14 Dec 2011 Phase-I/II clinical trials in Haemophilia B in USA (IV)
- 20 Apr 2011 Preclinical trials in Haemophilia B in USA (IV)